Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
13.827 / 17.026
#110610

Re: Farmas USA

ACAD

Se disparaaaaaaa  +18%

#110612

Re: Farmas USA

Y el día de brujas?? Cash is king.

#110613

Re: Farmas USA

Shares Spiking On An FDA Post Titled 'FDA analysis finds no new or unexpected safety risks associated with Nuplazid' For Hallucinations And Delusions Of Parkinson's

ACAD

#110614

Re: Farmas USA

esa noticia pinta muy bien esperemos que vuele la acción

ACAD

#110615

Re: Farmas USA

Eso es lo que tramaban estos dias, pues nada a ver si llega a 30$ y me dan pasta las call, por que las puts de momento se van...

Solo se que no se nada.

#110616

Re: Farmas USA

Acadia Pharma up 12% on favorable FDA analysis on Nuplazid

Sep. 20, 2018 12:37 PM ET|By:  Douglas W. House, SA News Editor 

ACADIA Pharmaceuticals ( ACAD +12.1%) is up on average volume in apparent response to an FDA post stating the it found no new safety risks associated with NUPLAZID (pimavanserin). Shares had been mired in a year-long downtrend initially stoked by mixed results from a mid-study evaluating NUPLAZID for the treatment of Alzheimer's disease psychosis. Safety concerns added to the bearishness.

Previously:  Acadia down 20% on FDA relook at Nuplazid safety data (April 25)

Previously:  Mid-stage study of Acadia's pimavanserin hits primary endpoint, but fails on key secondaries; shares down 7% (Nov. 6, 2017)

https://seekingalpha.com/news/3391868-acadia-pharma-12-percent-favorable-fda-analysis-nuplazid